Disease modifying trials in Alzheimer disease: Methodological and statistical issues

被引：0

作者：

Andrieu, S ^{[1
]}

Rascol, O

Lang, T

Grandjean, H

Vellas, B

机构：

[1] Fac Med Toulouse, INSERM, U558, F-31073 Toulouse, France

[2] CHU Toulouse, Serv Epidemiol, Toulouse, France

[3] CHU Toulouse, Serv Pharmacol, Toulouse, France

[4] CHU Toulouse, Serv Med Interne & Geriatr, Toulouse, France

来源：

JOURNAL OF NUTRITION HEALTH & AGING | 2006年 / 10卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

In order to establish that a drug has an impact on disease progression, a clinical trial must study both the symptomatic and the disease modifying effect of the drug. Disease modifying trials raise some methodological issues with regard to the choice of the design (parallel arm versus two-period design), of the outcome (clinical versus surrogate) and of the statistical analysis (management of missing data).

引用

页码：116 / 117

页数：2

共 50 条

[11] Methods for discerning disease-modifying effects in Alzheimer disease treatment trials
Kaye, JA
ARCHIVES OF NEUROLOGY, 2000, 57 (03) : 312 - 314
[12] Biomarkers in the Acceleration of Alzheimer's Disease Modifying Prevention Trials
Bateman, Randall
BIOLOGICAL PSYCHIATRY, 2014, 75 (09) : 135S - 135S
[13] Prevention trials in Alzheimer's disease: Design issues
Thal, L
NEUROBIOLOGY OF AGING, 2004, 25 : S91 - S91
[14] Disease-modifying trials in Alzheimer's disease: a European task force consensus
Vellas, Bruno
Andrieu, Sandrine
Sampaio, Cristina
Wilcock, Gordon
LANCET NEUROLOGY, 2007, 6 (01): : 56 - 62
[15] Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease
Dickerson B.C.
Sperling R.A.
NeuroRX, 2005, 2 (2): : 348 - 360
[16] Peyronie's Disease Intervention Trials: Methodological Challenges and Issues
Mueller, Alexander
Mulhall, John P.
JOURNAL OF SEXUAL MEDICINE, 2009, 6 (03): : 848 - 861
[17] Imaging-based measures of disease progression in clinical trials of disease modifying drugs for Alzheimer disease
Matthews, B
Siemers, ER
Mozley, PD
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2003, 11 (02): : 146 - 159
[18] Designing clinical trials to test disease-modifying agents: application to the treatment trials of Alzheimer's disease
Xiong, Chengjie
van Belle, Gerald
Miller, J. Philip
Morris, John C.
CLINICAL TRIALS, 2011, 8 (01) : 15 - 26
[19] Non-cognitive outcomes in trials of disease-modifying drugs for Alzheimer's disease
Zekry, D.
Graf, C. E.
Giannelli, S. V.
Gold, G.
Michel, J. -P.
EUROPEAN GERIATRIC MEDICINE, 2012, 3 (01) : 37 - 42
[20] Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research
Yiannopoulou, Konstantina G.
Anastasiou, Aikaterini, I
Zachariou, Venetia
Pelidou, Sygkliti-Henrietta
BIOMEDICINES, 2019, 7 (04)

← 1 2 3 4 5 →